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Background: Total mortality is one of the main endpoints in cardiovascular revascularization trials. As these trials include only individuals with known 
coronary artery disease (CAD), it seems intuitive that their total mortality would be increased relative to the general population. Although this assumption 
could have large implications in interpreting study results, its validity has not been previously investigated. Our goal was to evaluate the difference in 
relative mortality between the general population and those with proven CAD in drug-eluting stent (DES) trials. We hypothesized that total mortality in 
study populations would be greater than that of the general population, and would increase with increasing amounts of unstable CAD.
Methods: We found 44 DES studies with at least 1 year of follow-up. We calculated the total mortality of the patients in each study and compared 
this to the total mortality of the general U.S. population, adjusted for age & gender, generating a hazard ratio for the effect of study-inclusion on 
mortality. Studies were divided into 3 groups based on the amount of stable CAD, with a separate group for studies with only ST-elevation myocardial 
infarction (STEMI). We then calculated a weighted average of relative total mortality for each group.
Results: Relative mortality was 0.70 for those with a majority (> 60%) stable CAD, 1.12 for those with equal proportions (40-60%) stable & 
unstable CAD, 1.51 for those with a minority (<40%) of stable CAD, and 1.15 for trials limited to STEMI.
Conclusion: Individuals in studies where the majority of CAD was stable actually had a lower total mortality than the general population. Also, 
although increased mortality generally followed increased unstable disease, the total mortality in studies limited to STEMI (solely unstable CAD) 
was significantly less than studies with a mere majority unstable CAD, and nearly equal to studies with similar proportions of stable & unstable CAD. 
This study shows how a major endpoint for the evaluation of new treatments can be unexpectedly altered, not by the treatment, but by selecting for 
disease.
